6 Result: LON:SHP
Shire's First Prescription Eye Drop, Xiidra(TM) (lifitegrast ophthalmic solution) 5% Is Now Available in the U.S.
August 29th, 2016
Xiidra is the onlyprescription eye drop approved by the U.S. FDA for the treatment of both signs and symptoms of dry eye disease Resources are available to support patients seeking information regarding coverage and savings offers Xiidra is t. Read more
Shire Recommends ADS Holders Reject TRC Capital's "Mini-Tender Offer"
July 29th, 2016
Dublin, Ireland / CRWE PRESS RELEASE / July 29, 2016 – Shire plc (LSE: SHP) (NASDAQ: SHPG) has been notified of an unsolicited “mini-tender” offer made by TRC Capital Corporation (“TRC Capital”) to purchase up to 1,000,0. Read more
ONIVYDE(R) Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas who have Progressed Following Gemcitabine based Therapy
July 25th, 2016
The positive opinion is based on a pivotal Phase 3 study showing that ONIVYDE combined with chemotherapy significantly increased overall survival (OS) in patients with metastatic pancreatic cancer after previous gemcitabine based therapy Zug, Swit. Read more
Chronos Therapeutics Acquires Pre-clinical Programmes From Shire
July 20th, 2016
Expands Pipeline With Novel CNS Assets in a Transformative Deal Oxford, UK / CRWE PRESS RELEASE / July 20, 2016 - Chronos Therapeutics Ltd (Chronos), the private biotech company focused on ageing diseases, brain and nervous system disorders, today. Read more
Shire Receives FDA Breakthrough Therapy Designation for SHP621 and SHP625, Investigational Products for Rare Gastrointestinal Conditions
June 13th, 2016
Lexington, Mass. / CRWE PRESS RELEASE / June 13, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for two investigational products for r. Read more
Shire Receives FDA Complete Response Letter for Lifitegrast NDA and Plans to Respond with OPUS-3 Trial
October 18th, 2015
Topline results from OPUS-3 Trial expected before year-end Lexington, Mass. / CRWEPRESSRELEASE / October 16, 2015 – Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that the U.S. Food and Drug Administration (FDA) requested an additio. Read more
Want To Find Some News?
News By Industries
July 17th, 2018July 12th, 2018July 05th, 2018June 27th, 2018